Cervical Dysplasia - A Pipeline Analysis Report | Technavio
May. 12, 2018
LONDON--(BUSINESS WIRE)--May 12, 2018-- has announced its latest pipeline analysis report on the market. The report comprises a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat cervical dysplasia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180512005017/en/
Technavio has published a new pipeline analysis report on cervical dysplasia from 2018-2022. (Graphic: Business Wire)
This report offers a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are anticipated to play an essential role in the growth of the market during the forecast period.
Cervical dysplasia - market overview
is a condition in which solid cells on the cervix experience some unusual changes. It is caused by the human papillomavirus (HPV) infection in the cervix. HPV is a very common infection and is transmitted through sexual conduct. Cervical dysplasia is a pre-cancerous stage that can be mild or severe depending on the appearance of the abnormal cells. It is also known as cervical intraepithelial neoplasia (CIN). CIN 1 often does not require treatment whereas various surgeries or procedures are required for the treatment of CIN 2 or CIN 3.
According to a senior analyst at Technavio , “Mild dysplasia is the most common condition. In this stage, almost up to 70% of the cases regress on their own. This denotes that the cervical tissue comes back to normal without treatment. Moderate and severe dysplasia are less inclined to self-resolve and therefore, have a higher rate of developing cervical cancer.”
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Cervical dysplasia segmentation
This market research report segments the market based on therapies employed that includes monotherapy, RoA (intramuscular, topical, and oral), therapeutic modalities (small molecule, antibody targeting HPV, and DNA vaccine), targets for drugs under development (HPV 16, HPV 16/18 of E6/E7, and undisclosed), mechanism of action (immunostimulants, apoptosis stimulants and virus replication inhibitors, photosensitization, and DNA vaccine), and recruitment status (recruiting, active not recruiting, and completed).
Monotherapy refers to the use of a single drug to treat a disorder or a disease. In the current pipeline, 100% of the molecules that are being invested are monotherapy.
In case of intramuscular drugs, the drug is directly injected into the muscle. Around 50% of the total pipeline therapeutics are being developed for intramuscular RoA.
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180512005017/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 05/12/2018 12:10 PM/DISC: 05/12/2018 12:10 PM